- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02504424
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
January 28, 2019 updated by: AirXpanders, Inc.
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
This study is designed to allow existing investigators continued access to the AeroForm Tissue Expander to treat patients while AirXpanders completes a marketing application and during the review process by FDA.
Study Overview
Detailed Description
This is a prospective, multi-center, single arm, open-label, continued access clinical study.
Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and implanted with the investigational AeroForm Tissue Expander.
If the subject is having a bilateral procedure, the AeroForm expander will be implanted in each side.
Subjects will be followed until the first post-operative visit after explant of the tissue expander(s) and exchange for permanent implant(s).
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Greenbrae, California, United States, 94904
- Marin General Hospital
-
San Jose, California, United States, 95008
- Good Samaritan Hospital, San Jose
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316
- Broward Health Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02130
- Faulkner Hospital
-
Worcester, Massachusetts, United States, 01605
- University of Massachusetts Memorial Medical Center
-
-
New York
-
New York, New York, United States, 10032-3713
- Columbia University
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Presbyterian Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Subject is female between the ages of 18-70
- Subject requires tissue expansion as part of breast reconstruction
- Subject is able to provide written informed consent
- Subject is able and willing to comply with all of the study requirements
- Subject has the physical, perceptual and cognitive capacity to understand and manage the at home dosing regimen
Exclusion Criteria:
- Subject's tissue integrity is unsuitable for tissue expansion
- Subject has residual gross malignancy at the intended expansion site
- Subject has current or prior infection at the intended expansion site
- Subject has a history of failed tissue expansion or breast reconstruction
- Subject has any co-morbid condition determined by the Investigator to place the subject at an increased risk of complications (e.g., severe collagen vascular disease, poorly managed diabetes)
- Subject is taking any concomitant medications determined by the Investigator to place the subject at an increased risk of complications (e.g., Prednisone, Coumadin).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AeroForm Tissue Expander
AeroForm Tissue Expansion inflation with carbon dioxide by remote control
|
The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Breasts With Successful Tissue Expansion With Exchange to a Permanent Breast Implant Unless Exchange is Precluded by a Non-device Related Event
Time Frame: 6 months
|
The primary endpoint is analyzed per breast.
Breasts in which the expander is removed and/or replaced due to a device related adverse event or a device malfunction are counted as failures.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Breast With Successful Tissue Expansion With Exchange to Permanent Implant Including All Breasts in the Per Protocol Cohort.
Time Frame: 6 months
|
Secondary analysis is repeated including all breasts in the PP cohort (including non-device related failures).
The Treatment Success Rate by breast, based on the Per Protocol cohort, including all cause failures, is 95.2% (80/84).
One subject (2 breasts) are not included in the analyses due to not completing the second stage surgery and withdrawal of consent.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Daniel Jacobs, M.D., AirXpanders Chief Medical Officer
- Principal Investigator: Jeffrey Ascherman, M.D., Columbia University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 12, 2015
Primary Completion (Actual)
May 3, 2017
Study Completion (Actual)
September 26, 2017
Study Registration Dates
First Submitted
July 20, 2015
First Submitted That Met QC Criteria
July 21, 2015
First Posted (Estimate)
July 22, 2015
Study Record Updates
Last Update Posted (Actual)
January 29, 2019
Last Update Submitted That Met QC Criteria
January 28, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CTP-0005 AirXpanders
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on AeroForm Tissue Expander
-
AirXpanders, Inc.CompletedBreast Cancer | Breast ReconstructionAustralia
-
AirXpanders, Inc.Completed
-
Establishment LabsRecruiting
-
Lesley WongCompletedBreast CancerUnited States
-
Johns Hopkins UniversityCompletedQuality of Life | Breast Cancer | Postoperative Pain | Postoperative Nausea and Vomiting | Breast Prosthesis; PainUnited States
-
Cedars-Sinai Medical CenterSientra, Inc.CompletedBreast Cancer | Hereditary Breast and Ovarian Cancer Syndrome | Breast Implant; ComplicationsUnited States
-
Baxter Healthcare CorporationDuke UniversityRecruiting
-
Northwestern UniversityMentor Worldwide, LLCCompletedContour Irregularity of Reconstructed BreastUnited States
-
Stanford UniversityMarz Medical, Inc.Not yet recruitingTissue Expansion | Implant Based Breast ReconstructionUnited States
-
Vanderbilt University Medical CenterTerminatedPostoperative Pain | Complications | MastectomyUnited States